Selected Grants
COMBINE - ARLG 2.0 - DEPRU Site Budget (Yr8 of ARLG/Yr1 of ARLG 2.0)
Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2019 - 2026Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2021 - 2026A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety
Clinical TrialPrincipal Investigator · Awarded by Argenx BVBA · 2023 - 2026UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEMentor · Awarded by University of North Carolina - Chapel Hill · 2016 - 2026CIVICS Component C - Option 13A
ResearchInvestigator · Awarded by National Institutes of Health · 2019 - 2025COMBINE - ARLG 2.0 - DEPRU Site Budget (Yr8 of ARLG/Yr1 of ARLG 2.0)
Clinical TrialPrincipal Investigator · Awarded by DCRI-Duke-Site · 2019 - 2026Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Nipocalimab Administered to Adults with Generalized
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2021 - 2026A Long-Term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety
Clinical TrialPrincipal Investigator · Awarded by Argenx BVBA · 2023 - 2026UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEMentor · Awarded by University of North Carolina - Chapel Hill · 2016 - 2026CIVICS Component C - Option 13A
ResearchInvestigator · Awarded by National Institutes of Health · 2019 - 2025Evaluating Wnt-Modulators as a Therapy for Treatment of Arrhythmic Cardiomyopathy In Vivo
ResearchCollaborator · Awarded by Hartwell Foundation · 2022 - 2025Healthy Volunteer Study of CSF fluid and Oral Bioavailability of RR-HNK
ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2021 - 2024Phase I Single Ascending Dose and Multiple Ascending Dose Study of 2R,6R-Hydroxynorketamine
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2018 - 2024COVID-19 ASSOCIATED RISKS AND EFFECTS IN MYASTHENIA GRAVIS (CARE-MG)
ResearchPrincipal Investigator · Awarded by Myasthenia Gravis Foundation · 2021 - 2024COVID-19 Vaccine survey in MG
ResearchPrincipal Investigator · Awarded by Myasthenia Gravis Foundation · 2021 - 2023Defining the clinical phenotype and immunopathology of seronegative MG
ResearchPrincipal Investigator · Awarded by Myasthenia Gravis Foundation · 2021 - 2023Nerve Ultrasound for Diagnosis and Prognosis of GBS
ResearchAdvisor · Awarded by GBS/CIDP Foundation International · 2020 - 2023Neuromuscular ultrasound and electric impedance myography in CMT type 1A: a prospective longitudinal study
ResearchCo-Mentor · Awarded by American Neuromuscular Foundation · 2021 - 2023Serimmune/Duke Collaboration (II)
ResearchPrincipal Investigator · Awarded by SerImmune, Inc. · 2019 - 2023VTEU 18-0010.B1C1.0120_Task C Option 1
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2022VACCINE AND TREATMENT EVALUATION UNITS (VTEU) PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS TASK AREA B-D PHASE 1 PK TRIAL TO EVALUATE FOSFOMYCIN TASK ORDER 16-0058.B1C1D1.0076
ResearchSite PI · Awarded by National Institutes of Health · 2017 - 2022Task Area B-D Task Order 16-0058.B1C1D1.0076
ResearchInvestigator · Awarded by National Institutes of Health · 2017 - 2022VTEU Task Order 16-0058.B1C1D1.0076 - Task D
ResearchInvestigator · Awarded by National Institutes of Health · 2017 - 2022Prospective Multicenter Observational Cohort Study of Comparative Effectiveness of Disease-Modifying Treatments for Myasthenia Gravis (MG)
Clinical TrialCo Investigator · Awarded by Patient-Centered Outcomes Research Institute · 2017 - 2022The NAD+ Baseline Study
Clinical TrialPrincipal Investigator · Awarded by Elysium Health · 2019 - 2022First-in-human SAD & MAD trials for MW151, a novel Alzheimer's disease drug candidate that attenuates proinflammatory cytokine dysregulation
Clinical TrialPrincipal Investigator · Awarded by University of Kentucky · 2019 - 2022Real World Outcomes of Surgical and Medical Management in Myasthenia Gravis
ResearchMentor · Awarded by American Academy of Neurology · 2019 - 2022A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efg
Clinical TrialPrincipal Investigator · Awarded by Argenx BVBA · 2021 - 2022A Phase 3, Placebo Controlled, Randomized, Observer-Blinded Study to Evaluate the Efficacy, Safety, and Tolerability of a Clostridium Difficile Vaccine in Adults 50 Years of Age and Older
Clinical TrialPrincipal Investigator · Awarded by Pfizer, Inc. · 2017 - 2022A Phase 2, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and
Clinical TrialPrincipal Investigator · Awarded by Takeda Pharmaceutical Company Limited · 2021 - 2022Biomarkers predicting response to eculizumab in MG (NonFed)
ResearchMentor · Awarded by The George Washington University · 2021 - 2022Biomarkers predicting response to eculizumab in myasthenia gravis
ResearchMentor · Awarded by The George Washington University · 2021 - 2022RARE DISEASE NETWORK FOR MYASTHENIA GRAVIS
ResearchPrincipal Investigator · Awarded by The George Washington University · 2019 - 2022MG 302 Extension (RAISE XT)
Clinical TrialPrincipal Investigator · Awarded by Ra Pharmaceuticals, Inc · 2020 - 2022RAISE
Clinical TrialPrincipal Investigator · Awarded by Ra Pharmaceuticals, Inc · 2020 - 2021UCB-UNC Fellowship in Neurology Clinical Drug Development
Inst. Training Prgm or CMEPrincipal Investigator · Awarded by University of North Carolina - Chapel Hill · 2019 - 2021DN44 Acceleron extension
Clinical TrialPrincipal Investigator · Awarded by Acceleron Pharma · 2019 - 2021UNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training Program
Inst. Training Prgm or CMEMentor · Awarded by University of North Carolina - Chapel Hill · 2020 - 2021Metabolic Pathways Of Pathogenic Th17 Cells In Myasthenia Gravis
ResearchPrincipal Investigator · Awarded by Myasthenia Gravis Foundation · 2020 - 2021RTOP 18-0006 Option 1 / Protocol Implementation
Clinical TrialSite PI · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2021MOM-M281-005
Clinical TrialPrincipal Investigator · Awarded by Momenta Pharmaceuticals, Inc. · 2019 - 2021MOM-M281-004
Clinical TrialPrincipal Investigator · Awarded by Momenta Pharmaceuticals, Inc. · 2018 - 2021Pathogenic Th17 cell pathology in CIDP
ResearchCo Investigator · Awarded by GBS/CIDP Foundation International · 2019 - 2021Collaborative Agreement between Duke University and True North Therapeutics, Inc.
ResearchPrincipal Investigator · Awarded by Bioverativ · 2017 - 2021Mechanisms of Immune Dysregulation in Chronic Inflammatory Demyelinating Polyneuropathy
FellowshipPrincipal Investigator · Awarded by AANEM Foundation for Research & Education · 2019 - 2020Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects
Clinical TrialPrincipal Investigator · Awarded by Stanford University · 2018 - 2020P1CTU_Task Order 16_Protocol Implementation
Clinical TrialSite PI · Awarded by National Institute of Allergy and Infectious Diseases · 2017 - 2020A MULTICENTER, RANDOMIZED, INVESTIGATOR- AND SUBJECT-BLIND, PLACEBO-CONTROLLED, TREATMENT SEQUENCE STUDY EVALUATING THE SAFETY, TOLERABILITY, AND EFFICACY OF UCB7665 IN SUBJECTS WITH MODERATE TO SEVERE MYASTHENIA GRAVIS
Clinical TrialPrincipal Investigator · Awarded by UCB Biosciences Inc. · 2017 - 2020VTEU Task C Option 1 Protocol 14-0024.C1D1.0037
ResearchSenior Investigator · Awarded by National Institutes of Health · 2018 - 2020VTEU Task C Base Protocol 14-0024.C1D1.0037
ResearchSenior Investigator · Awarded by National Institutes of Health · 2015 - 2020Inpatient Double-Blind Placebo-Controlled Withdrawal Study of 3,4-Diaminopyridine Base (3,4-DAP) in Subjects with Known Lambert-Eaton Myasthenic Syndrome (LEMS) [JPC 3,4-DAPPER]
ResearchPrincipal Investigator · Awarded by Jacobus Pharmaceutical Company, Inc. · 2018 - 2020RTOP 18-0006 Base / Protocol Development
ResearchSite PI · Awarded by National Institute of Allergy and Infectious Diseases · 2019 - 2020VAC057: Assess the reactogenicity, safety, and immunogenicity of a live attenuated universal influenza vaccine
Clinical TrialPrincipal Investigator · Awarded by PATH · 2017 - 2020Immunological biomarker studies in myasthenia gravis
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2014 - 2020ACE-083_DCRU
Clinical TrialPrincipal Investigator · Awarded by Acceleron Pharma · 2018 - 2019Immunologic Changes in the Treatment of Myasthenia Gravis
ResearchPrincipal Investigator · Awarded by Ra Pharmaceuticals, Inc · 2017 - 2019Role of CD4 T cell subsets as drivers of MG disease
Clinical TrialPrincipal Investigator · Awarded by Myasthenia Gravis Foundation · 2016 - 2019A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients with Neutrophilic Skin Diseases
Clinical TrialPrincipal Investigator · Awarded by Eli Lilly and Company · 2016 - 2019VTEU 18-0010.B1C1.0120_Task B Base
ResearchCo Investigator · Awarded by National Institutes of Health · 2019 - 2019P1CTU Protocol Development for 17-0033 (Base)
Clinical TrialSite PI · Awarded by National Institutes of Health · 2017 - 2019A Phase 1b MAD Study of TT301/MW189
Clinical TrialPrincipal Investigator · Awarded by University of Kentucky · 2017 - 2019ITI Parkinson's Disease Study
Clinical TrialPrincipal Investigator · Awarded by Intra-Cellular Therapies, Inc. · 2017 - 2018Phase I Open Label Study to Determine the Pharmacokinetics, Pharmacodynamics, and Safety of IV Ganaxolone in Healthy Adults
Clinical TrialPrincipal Investigator · Awarded by Marinus Pharmaceuticals, Inc. · 2016 - 2018AANEM Autoimmune Neuromuscular Disorders Fellowship
FellowshipPrincipal Investigator · Awarded by AANEM Foundation for Research & Education · 2017 - 2018Acetylcholine receptor binding B cells as biomarker for myasthenia gravis
ResearchPrincipal Investigator · Awarded by AFM-Telethon · 2017 - 2018Study to Evaluate the Efficacy and Safety of Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Symptomatic Subjects with Generalized Myasthenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Grifols USA, LLC · 2016 - 2018Study to Evaluate the Efficacy and Safety of Immune globulin (Human), 10% Caprylate/Chromatography Purified (IGIV -C) as a Corticosteroid Dsparing Agent in Corticosteroid Dependent Patients with Generalized Myathenia Gravis
Clinical TrialPrincipal Investigator · Awarded by Grifols USA, LLC · 2016 - 2018PTN TO 23-The Effect of Obesity on the Pharmacokinetics of Pantoprazole in Children
Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2013 - 2018P1CTU_Task Order 16_Protocol Development
ResearchSite PI · Awarded by National Institute of Allergy and Infectious Diseases · 2017 - 2017High Impact Pilot Project on Myasthenia Gravis and Related Neuromuscular Junction Disorders
ResearchPrincipal Investigator · Awarded by Myasthenia Gravis Foundation · 2014 - 2017Immunologic Studies in Myasthenia Gravis
ResearchPrincipal Investigator · Awarded by SerImmune, Inc. · 2014 - 2017Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety, Tolerability, and Pharmacokinetics of a Single Escalating Dose and Repeated Doses of CN-105 in Healthy Adult Subjects.
Clinical TrialPrincipal Investigator · Awarded by CereNova, LLC · 2015 - 2016DAP Phase I PK/PD Analysis Budget
ResearchPrincipal Investigator · Awarded by Jacobus Pharmaceutical Company, Inc. · 2016 - 2016External Relationships
- argenx US, Inc
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.